title: Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin.
abstract: BACKGROUND
  The aim was to investigate whether intragastric pH, meal-stimulated gastrin release, or demographic factors predict the outcome of Helicobacter pylori treatment.
  
  
  METHODS
  Thirty-six patients with H. pylori infection were investigated with 24-h intragastric pH registration and meal-stimulated gastrin release before and during treatment with 20 mg omeprazole twice daily and 750 mg amoxicillin twice daily for 14 days. The influence of age, sex, smoking, ethnic origin, pH, and gastrin on treatment outcome were analysed with logistic regression.
  
  
  RESULTS
  Eradication of H. pylori was achieved in 18 of 34 (53%) patients. The univariate analysis showed that age, ethnic origin, more than 84.2% of the time with pH above 4, and continuous periods longer than 156 min with intragastric pH above 6 were significantly associated with successful treatment of H. pylori. In the multivariate analysis only the two pH variables were found to be independent factors for predicting treatment outcome.
  
  
  CONCLUSIONS
  The outcome of H. pylori treatment with omeprazole and amoxicillin may depend on several factors, such as age, ethnic origin, and a pronounced acid suppression. However, the only factor of independent importance in this study was prolonged and profound acid inhibition.
authors.affiliation: Dept. of Surgical and Medical Gastroenterology and Hepatology, Huddinge University Hospital, Karolinska Institute, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Sjöstedt
authors.forename: M
authors.initials: M
authors.lastname: Sagar
authors.forename: G
authors.initials: G
authors.lastname: Lindberg
authors.forename: B
authors.initials: B
authors.lastname: Wikström
authors.forename: C E
authors.initials: CE
authors.lastname: Nord
authors.forename: R
authors.initials: R
authors.lastname: Seensalu
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000208:ethnology / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D010406:Penicillins / Q000627:therapeutic use*; D017494:Proton Pumps; D012737:Sex Factors; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D010406:Penicillins; D017494:Proton Pumps; D000658:Amoxicillin; D009853:Omeprazole